
    
      This is an open-label, multicenter pharmacokinetic study of HD of adolescent PD patients
      receiving erythropoietin. Patients between the ages of 12 and 18 were administered 100mg of
      iron sucrose, undiluted by slow IV push over 5 minutes, and underwent serial blood draws. The
      patients were subsequently followed for 7 days for safety endpoints.
    
  